Results of Five-Year Outpatient Follow-Up of Patients With Heart Failure in a Specialized Center

N G Vinogradova1, D S Polyakov2, I V Fomin3

  • 1Lobachevsky National Research Nizhny Novgorod State University.

Kardiologiia
|December 5, 2024
PubMed

Insights

Specialized care significantly reduces mortality in chronic heart failure (CHF) patients post-acute decompensated heart failure (ADHF). Regular follow-up at a CHF center lowers risks of all-cause death, cardiovascular death, and death from recurrent ADHF over five years.

Area of Science:

  • Cardiology
  • Public Health
  • Clinical Medicine

Background:

  • Chronic heart failure (CHF) management requires ongoing care after acute decompensated heart failure (ADHF) hospitalizations.
  • Real-world clinical practice and specialized care settings may influence long-term outcomes.

Purpose of the Study:

  • To assess the five-year risks of all-cause death (ACD), cardiovascular death (CVD), and death from recurrent ADHF.
  • To compare outcomes between patients receiving specialized CHF care (cCHF) versus standard outpatient care (OPI).

Main Methods:

  • A prospective cohort observational study of 942 patients post-ADHF.
  • Comparison of outcomes between a specialized CHF center group (cCHF, n=510) and an outpatient/polyclinic institution group (OPI, n=432).
  • Five-year follow-up analyzing causes of death using medical records and postmortem data; statistical analysis via R package.

Main Results:

  • All-cause death (ACD) was significantly lower in the cCHF group (32.3%) compared to the OPI group (53.5%) (p<0.001).
  • Specialized follow-up (cCHF) was associated with reduced risk of ACD (HR 2.07), CVD (HR 1.94), recurrent ADHF death (HR 2.4), and composite mortality (HR 2.2).
  • Mortality risks were higher in HFmrEF and HFrEF compared to HFpEF; increased age and Clinical Condition Assessment Scale scores worsened prognosis, while female sex, higher systolic BP, and longer 6-minute walk test improved it.

Conclusions:

  • Absence of specialized outpatient CHF follow-up increases risks of all-cause death, cardiovascular death, and death from recurrent ADHF over five years.
  • Recurrent ADHF and sudden cardiac death (SCD) were the primary causes of mortality in both groups.
  • Specialized care is crucial for improving long-term survival in CHF patients post-ADHF hospitalization.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
2
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
517
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316